Method of treating melanoma using an inhibitor of an atypical protein kinase C
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 16, 2021
Grant Date -
Dec 7, 2017
app pub date -
Jun 2, 2017
filing date -
Jun 2, 2016
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention pertains to a method of treating melanoma by administering to a subject in need thereof, a composition comprising a therapeutically effective amount of an inhibitor of PKC-ζ and/or PKC-ι. Non-limiting examples of an inhibitor of PKC-ζ and/or PKC-ι include ICA-1 and ACPD. The invention also provides PKC-ζ and/or PKC-ι as biomarkers for identifying a melanoma in a subject as likely to be responsive or non-responsive to a therapy using an inhibitor of PKC-ζ and/or PKC-ι. Accordingly, a method of identifying a subject having a melanoma as being responsive or non-responsive to a melanoma therapy with an inhibitor of PKC-ζ and/or PKC-ι based on the levels and/or activity of PKC-ζ and/or PKC-ι mRNA or protein in the melanoma cells from the subject are also provided.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully